Therapeutic Area | MeSH |
---|---|
infections | D007239 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
mycobacterium infections | — | D009164 | A31.9 |
tuberculosis | EFO_0000774 | D014376 | A15-A19 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 9 | 30 | 19 | 6 | 17 | 75 |
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 3 | 36 | 15 | 5 | 7 | 58 |
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 4 | 6 | 5 | 6 | 21 |
Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 6 | 8 | 4 | 4 | 20 |
Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | 1 | 2 | 3 |
Spinal tuberculosis | D014399 | — | A18.01 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Meningeal tuberculosis | D014390 | — | A17.0 | 1 | 7 | 2 | — | — | 8 |
Hiv | D006678 | — | O98.7 | — | 2 | 2 | — | 1 | 5 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 2 | — | 1 | 3 |
Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | — | 2 |
Extensively drug-resistant tuberculosis | D054908 | — | — | — | 1 | 2 | — | — | 2 |
Pneumonia | D011014 | EFO_0003106 | — | — | 1 | 1 | — | — | 1 |
Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | — | 1 | 1 | — | — | 1 |
Anterior uveitis | D014606 | EFO_1000811 | — | — | — | 1 | — | — | 1 |
Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | — | 1 |
Bacterial infections | D001424 | — | A49 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sars-cov-2 | D000086402 | — | — | — | 1 | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | — | 1 | — | — | — | 1 |
Aids-related complex | D000386 | EFO_0007137 | B20 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
Motor activity | D009043 | EFO_0003940 | — | — | — | — | — | 1 | 1 |
Coinfection | D060085 | — | — | — | — | — | — | 1 | 1 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 1 | 1 |
Drug common name | Pyrazinamide |
INN | pyrazinamide |
Description | Pyrazinecarboxamide is a monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis. It has a role as an antitubercular agent and a prodrug. It is a member of pyrazines, a N-acylammonia and a monocarboxylic acid amide. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1cnccn1 |
PDB | — |
CAS-ID | 98-96-4 |
RxCUI | — |
ChEMBL ID | CHEMBL614 |
ChEBI ID | 45285 |
PubChem CID | 1046 |
DrugBank | DB00339 |
UNII ID | 2KNI5N06TI (ChemIDplus, GSRS) |